OPKO Health Responds to Law Firm Notice of Investigation
August 23 2016 - 12:47PM
Business Wire
OPKO Health, Inc. (NYSE:OPK), is aware of a press release
by Purcell Julie & Lefkowitz, LLP, a class action litigation
firm, that it is investigating the Company for an alleged potential
breach of fiduciary duty claim involving the Company’s Board of
Directors. The Company has not received any notification or
information from Purcell Julie & Lefkowitz regarding its
investigation of any potential breach of fiduciary duty or other
claim against OPKO’s Board of Directors. Nor have any such claims
or allegations been made by any shareholders, other law firms or
regulatory bodies. OPKO’s attempts to contact the law firm have
gone unanswered. The Company does not believe there is any basis or
merit behind the investigation and will vigorously defend itself
should any formal allegations or claims be made.
About OPKO Health, Inc.
OPKO Health, Inc. is a diversified healthcare company that seeks
to establish industry-leading positions in large, rapidly growing
markets. Our diagnostics business includes Bio-Reference
Laboratories, the nation's third-largest clinical laboratory with a
core genetic testing business and a 420-person sales force to drive
growth and leverage new products, including the 4Kscore prostate
cancer test and the Claros 1 in-office immunoassay platform. Our
pharmaceutical business features RAYALDEE, an FDA approved
treatment for SHPT in stage 3-4 CKD patients with vitamin D
insufficiency, and VARUBI™ for chemotherapy-induced nausea and
vomiting (oral formulation launched by partner Tesaro and IV
formulation PDUFA is January 2017). Our biologics business includes
hGH-CTP, a once-weekly human growth hormone injection (in Phase 3
and partnered with Pfizer), a long-acting Factor VIIa drug for
hemophilia (in Phase 2a) and a long acting oxyntomodulin for
diabetes and obesity (in Phase 1). We also have production and
distribution assets worldwide, multiple strategic investments and
an active business development strategy. More information is
available at www.opko.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains "forward-looking statements," as
that term is defined under the Private Securities Litigation Reform
Act of 1995 (PSLRA), which statements may be identified by words
such as "expects," "plans," "projects," "will," "may,"
"anticipates," "believes," "should," "intends," "estimates," and
other words of similar meaning, including statements regarding
whether a formal investigation or legal proceeding will be
commenced against OPKO, as well as other non-historical statements
about our expectations, beliefs or intentions regarding our
business, technologies and products, financial condition,
strategies or prospects. Many factors could cause our actual
activities or results to differ materially from the activities and
results anticipated in forward-looking statements. These factors
include those described in our Annual Reports on Form 10-K filed
and to be filed with the Securities and Exchange Commission and in
our other filings with the Securities and Exchange Commission. The
forward-looking statements contained in this press release speak
only as of the date the statements were made, and we do not
undertake any obligation to update forward-looking statements. We
intend that all forward-looking statements be subject to the
safe-harbor provisions of the PSLRA.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160823006090/en/
CompanyOPKO Health, Inc.Tara Mackay, 305-575-4100Investor
RelationsorMediaRooney & AssociatesTerry Rooney,
212-223-0689trooney@rooneyco.comorMarion Janic,
212-223-4017mjanic@rooneyco.comorInvestorsLHAAnne Marie
Fields, 212-838-3777afields@lhai.comorBruce Voss,
310-691-7100bvoss@lhai.com
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Apr 2024 to May 2024
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From May 2023 to May 2024